First-Pass Metabolism Explained

The liver gets first say

Roughly 40–75% of an oral dose of some compounds never makes it to systemic circulation intact. That number stopped me cold the first time I pulled it from a pharmacokinetics textbook. I'd been cataloguing papers on cannabinoid formulations for about a week, and it suddenly explained why the same nominal dose of a compound can produce wildly different outcomes depending entirely on how it's delivered. First-pass metabolism is the reason, and it's one of those concepts that genuinely reshapes how you read a clinical paper once you understand it.

The short version: swallow something, and before it ever reaches your bloodstream in a meaningful concentration, it has to survive the gastrointestinal tract, get absorbed across the intestinal wall, and then pass through the liver via the portal vein. The liver is not passive. It is, functionally, a chemical processing plant, and it has strong opinions about what it lets through.

What actually happens, step by step

After you swallow a compound, it dissolves in the gut and crosses the intestinal epithelium , the lining cells of the small intestine. Some metabolic activity already occurs here; certain enzymes (CYP3A4 in particular) are expressed in intestinal wall tissue and begin biotransformation before the compound even reaches the liver. This is sometimes called "intestinal first-pass" and is separate from, but additive to, what happens next.

From the intestinal wall, absorbed molecules drain into the portal circulation , a dedicated venous system that routes blood from the gut directly to the liver. There, hepatocytes (liver cells) go to work. Cytochrome P450 enzymes, UDP-glucuronosyltransferases, sulphotransferases and a range of other enzyme families convert lipophilic (fat-loving) molecules into more water-soluble metabolites. Some of those metabolites are biologically active in their own right. Others are inert. Some are conjugated and excreted into bile, completing a loop called enterohepatic recirculation.

What emerges from the liver and enters the systemic circulation is a mixture: unchanged parent compound plus metabolites, in proportions that vary with the specific molecule, the individual's enzyme expression (which is partly genetic), liver health, co-administered substances, and even fed/fasted state.

This is why bioavailability , the fraction of a dose that reaches systemic circulation in an active form; is often substantially lower for oral routes than for, say, inhalation or intravenous delivery. It's also why understanding pharmacokinetics as a whole, not just dosing numbers, matters when you're reading research.

The cannabinoid case study

Cannabidiol is a useful example, partly because its oral bioavailability has been studied reasonably well relative to other cannabinoids. Published estimates for oral CBD bioavailability in humans are quite variable, generally cited somewhere between 6% and 19% in fasted conditions, though fat co-administration can substantially increase absorption. A 2018 review in Frontiers in Pharmacology summarised the available human pharmacokinetic data and noted that the high lipophilicity of CBD, combined with significant intestinal and hepatic first-pass extraction, accounts for the low and variable oral bioavailability.

THC faces a similar, arguably more complicated picture. When THC undergoes hepatic first-pass metabolism, one of the primary metabolites is 11-hydroxy-THC (11-OH-THC), which is itself pharmacologically active and can cross the blood-brain barrier. The ratio of parent compound to 11-OH-THC in systemic blood after oral ingestion is quite different from the ratio after inhalation, a fact that has practical implications for the onset, duration, and character of any pharmacological effect. This metabolite dynamic doesn't exist to the same degree via inhaled routes, because inhaled THC bypasses the liver on its first pass through the lungs into systemic circulation.

Honestly, this single metabolic difference goes a long way toward explaining why the pharmacology research for inhaled versus oral cannabinoid preparations can look so different, even at nominally equivalent doses.

Why formulation researchers care so much about this

Pharmaceutical formulators have spent decades trying to reduce or circumvent first-pass extraction where it limits a compound's utility. The approaches fall into a few broad categories.

Sublingual and buccal delivery places a formulation under the tongue or against the cheek mucosa. The oral mucosa has a rich capillary network that drains into the jugular vein rather than the portal vein, allowing a fraction of the absorbed dose to bypass hepatic first-pass metabolism entirely. Absorption this way is not complete; saliva dilutes the preparation, and some is inevitably swallowed, but for molecules that survive mucosal absorption, the pharmacokinetic profile can differ meaningfully from straight oral ingestion.

Transdermal delivery, patches or gels applied to skin; similarly bypasses the GI-liver axis, though the skin itself presents a significant permeability barrier for highly lipophilic molecules.

Inhalation routes the compound directly from the pulmonary circulation into systemic blood with essentially no hepatic first-pass effect, which is why inhaled bioavailability for cannabinoids is generally estimated much higher than oral (some papers cite 10–35% for inhaled THC, depending on technique, still not 100%, because lung deposition is inefficient).

Lipid-based formulations, micro-emulsions, self-emulsifying drug delivery systems, nanoparticle encapsulation; aim to improve intestinal absorption and in some cases shift absorbed molecules into the lymphatic system rather than the portal vein, partially circumventing hepatic first-pass. This is an active area of formulation research for highly lipophilic plant-based compounds.

Individual variation: the part that rarely makes it into popular articles

CYP enzyme expression varies significantly between individuals. Genetic polymorphisms, particularly in CYP2C9, CYP3A4, and CYP2C19, mean that two people taking an identical oral dose of the same compound can end up with very different systemic exposures. This isn't trivial. A "poor metaboliser" of CYP2C9 substrates will have a slower first-pass extraction and thus higher exposure to the parent compound. A "rapid metaboliser" will see more of it converted before it ever reaches the bloodstream.

Age, sex, body composition, liver function, and concurrent medications all layer on top of that genetic baseline. Some plant-derived compounds are known inhibitors or inducers of CYP enzymes themselves, which means they can alter the first-pass metabolism of other substances taken at the same time. This interaction potential is one reason that any medicinal use of plant-based products should involve a prescriber who knows the full medication picture; and in Australia, products containing scheduled cannabinoids are prescription-only under the Poisons Standard, requiring either a Special Access Scheme application or prescribing by an Authorised Prescriber.

I'll admit I got this wrong for years in a general sense: I assumed first-pass metabolism was a simple, fixed reduction. It isn't. It's a dynamic, variable, person-specific, dose-specific, formulation-specific process.

What this means for reading cannabinoid and phytomedicine research

When you're reading a study on an oral cannabinoid preparation, first-pass metabolism is one of the first things worth checking in the methods section. What was the formulation? Oily solution, hard capsule, soft-gel, nanoemulsion? Was it taken fasted or with food? What was the dosing interval, and did the trial account for accumulation of active metabolites over repeated dosing?

These questions matter because the same nominal dose of, say, a full-spectrum oil versus an isolated compound in a lipid carrier will produce different plasma profiles, partly because the matrix affects intestinal absorption and the balance of first-pass extraction. The entourage effect hypothesis, which proposes interactions between cannabinoids, terpenes, and other phytochemicals, is partly a pharmacokinetic question as much as a pharmacodynamic one, how the components interact at the absorption and metabolism stages is still not well resolved in the literature.

I was reorganising a batch of secondhand pharmacology texts I'd picked up at a Paddington estate sale last month, mostly 1990s editions, well past their use-by date clinically, but the foundational chapters on hepatic clearance haven't really changed; and it struck me that these principles have been understood for a long time. The application to plant-based medicine is relatively new territory, though. Good-quality human pharmacokinetic data for many cannabinoids and phytomedicines remains genuinely sparse. That's worth holding in mind whenever a formulation claim sounds very confident.

The first-pass metabolism glossary entry here covers the definitional basics if you want a quicker reference. For the deeper read on how cannabinoid pharmacology fits into this picture, the CBD and THC pages set some useful context.

Sources

• Millar et al. (2018), "A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans", Frontiers in Pharmacology (via NCBI)
• Guidance on the use of medicinal cannabis in Australia, Therapeutic Goods Administration (TGA)
• Thummel & Wilkinson (StatPearls), "Drug Metabolism"; NCBI Bookshelf
• Cannabis drug facts, Alcohol and Drug Foundation (ADF)

, Tom Whitfield, Health librarian, references & fact-checking